Sealy — Investor Presentation (July 2011)
31 slides from Sealy's investor presentation, Jul 1, 2011
Slide 1: Sealy. Whatever you do in bed, supports it.
Sealy. Whatever you do in bed, supports it. gee f 4Posturepedic embody July 2011
Slide 2: Forward-Looking Statements
1 Forward-Looking Statements This document contains forward-looking statements within the meaning of the safe harbor provisions of the Securities Litigation Reform Act of 1995. Terms such as “expect,” “believe,” “continue,” and “grow,” as well as similar comments, are forward-looking in nature. Alth
Slide 3: Investment Highlights
2 Investment Highlights Stabilizing Industry Fundamentals with Attractive Long-Term Prospects Leading Global Brand with Significant Scale Innovative Market Leader with Broadest Branded Product Portfolio Industry Leading Advertising and Digital Media Assets Unprecedented Opportunity to Gain Profitabl
Slide 4: Company Overview
3 Company Overview Leading global bedding manufacturer with broadest portfolio of established brands Global Sales of $1.2Bn in Fiscal 2010 #1 - U.S. Market Position for over 20 years #1 - Canada and Mexico Industry’s Broadest Product Portfolio – Innerspring and Specialty Industry’s Largest Sales, Ma
Slide 5: Overview of Brands
4 Overview of Brands Innerspring offering represents ~50% of total Company portfolio Exceeded goal of shipping the line to at least 60% of our retail partners by Memorial Day. Actual shipped over 80%. Goal is to gain innerspring market share in 2H 2011 Premium price point, specialty offering introdu
Slide 6: Bedding Industry Demand Drivers
5 Bedding Industry Demand Drivers Approximately two-thirds of total industry revenues Historical 9-10 year replacement cycle Replacement Demand Strong long-term industry growth has been driven consistently by these principal factors Population Growth GDP Per Capita + Total Home Sales Innovative Prod
Slide 7: Stabilizing Industry Fundamentals with Attractive Long-Term Prospects
6 Stabilizing Industry Fundamentals with Attractive Long-Term Prospects Source: ISPA ¹ Source: Bureau of Economic Analysis, Congressional Budget Office Note: 2010 industry sale numbers are based on ISPA Bedding Barometer reported growth Positive demographic trends and resilient growth following rece
Slide 8: Current U.S. Market Environment
7 Current U.S. Market Environment Significant opportunities for Sealy in midst of challenging global macro-economic environment Economic Environment GDP, housing and credit markets have impacted unit sales Industry Environment Macroeconomic environment is becoming more challenging in both the U.S. a
Slide 9: #1 U.S. Market Position for over 20 Years
8 #1 U.S. Market Position for over 20 Years Leading competitor in fragmented market Significant global scale (#1 market share in Canada & Mexico) Broadest product and price point diversity Vertical integration – Innerspring and Specialty product lines Capital structure stability – withstand downturn
Slide 10: Product Portfolio Breadth
9 Product Portfolio Breadth Industry’s strongest portfolio of brands covering all price points and technologies Retail Price Point <$500 $500-999 $1,000-1,999 >$1,999 Technology Entry Innerspring Premium Innerspring High End Innerspring Latex / Visco 2010 U.S. Market Size $5.9Bn * $1.3Bn $1.9Bn $1.6
Slide 11: Net Sales by Geography FY 2010
10 Net Sales by Geography FY 2010 Strong Brand and Geographic Diversity Established U.S. branded products with global market presence Net Sales by Brand - Domestic FY2010 US Sales $0.95 Bn U.S. Canada Other 78.5% 14.1% 7.4% 1H 2011 Net Sales: $626.8 m Net Sales $1.2 Bn Canada 15% U.S. 78% Other 7% S
Slide 12: Global Market Opportunity
11 Global Market Opportunity Flexibility to utilize multiple business models to capture profitable market share Canada & Mexico Rest of the World Geography Business Model Retailer Network Vertical Integration Licensing Agreements & Joint Ventures Leverage U.S. distribution model strengths Build on #
Slide 13: 2011 Key Priorities
12 2011 Key Priorities Continue to Manage the Cost Structure Return The Domestic Business to Robust Top-line Growth De-lever the Balance Sheet Inflation counter measures and value engineering offsets Productivity gains in the components and bedding plants Vigilance to prevent costs from creeping bac
Slide 14: 2011 Product Launch – Next Generation Posturepedic
13 2011 Product Launch – Next Generation Posturepedic Line offers consumer-tested aesthetics, simple selling story & 3 new coils Introduction of encased-coil helping drive slot expansions and share gains Posturepedic launch was the fastest launch in Company history driven by strong customer demand a
Slide 15: Increase Specialty Distribution – Embody
14 Increase Specialty Distribution – Embody Have recently launched product at two major sleep shops Company focused on driving success in these benchmark accounts and then translating that success into additional distribution Strong retailer economics and retailer associate commission structures in
Slide 16: Industry Leading Advertising and Digital Media Assets
15 Industry Leading Advertising and Digital Media Assets New National Advertising focused on optimizing the latest Posturepedic Launch Innovative way to maximize Sealy’s significant co-op spend ($135m in FY 2010) Campaign exceeding expectations year-to-date “After-Glow” spot has received over 1.1 mi
Slide 17: New Product Introduction
16 New Product Introduction Illustrative Gross Margin Impact throughout a product launch cycle Discounts on old line to maintain velocity during product transition Floor sample discounts on new products Temporary labor inefficiencies related to new product introductions Post: New line rolled out – a
Slide 18: Management Focus
17 Management Focus Culture of innovation, cost improvement, accountability, and continuous improvement Management team has significantly repositioned the Company to drive long-term success Product Development Culture Cost Reduction Accountability Retailer and Supplier Partnerships Benchmarks for Fu
Slide 19: Financial Review
18 Financial Review
Slide 20: Net Sales Summary Financial Performance
19 Net Sales Summary Financial Performance (ex Discontinued Ops) Quarterly financial results – through Q2 2011 Gross Profit Adjusted EBITDA Q2 2011 – Commentary Total Net Sales were $321.3 million Results reflect $12.7 million of incremental investment made in product portfolio and brand, with the N
Slide 21: Q2 2011 Adjusted EBITDA Bridge
20 Q2 2011 Adjusted EBITDA Bridge Costs associated with the Posturepedic launch were $12.7 million Year to date Adjusted EBITDA was impacted by: Additional $12.7mm of product launch expenses, national advertising spend and margin impact of old line (soft Posturepedic mix and “close out pricing) $3.9
Slide 22: Free Cash Flow Trend Analysis
21 Free Cash Flow Trend Analysis Reduced leverage ratio (excluding the Convertible PIK notes) a half turn since May 2009 refinancing (4.03x to 3.49x) Material costs continue to trend up – continue to apply aggressive cost efficiency programs to mitigate risks Took pricing action and delivery surchar
Slide 23: Debt Maturities
22 Debt Maturities No near-term amortization payments Strong liquidity – undrawn revolver and strong cash balance Cash pay leverage ratio of 3.49x as of 5/29/11 Pro Forma Debt Maturity Profile ($ mm) Enhanced financial flexibility and liquidity to support strategic initiatives and de-lever Currently
Slide 24: Steady Cash Pay Interest
23 Steady Cash Pay Interest Cash Pay interest levels have declined following recent deleveraging Debt Instrument $ Amount Interest Rate Senior Secured Notes - 2016 $305 million * 10.875% Senior Sub Notes - 2014 $269 million 8.250% ABL Revolver - 2013 $100 million (undrawn) — Convertible PIK - 2016 $
Slide 25: Potential For Future Deleveraging
24 Potential For Future Deleveraging Convertible PIK notes soft call in 2012 is a potentially significant deleveraging event in addition to utilizing strong free cash flow generation for opportunistic calls/market purchases of senior notes Includes reduction for original issue discount of $9.6 milli
Slide 26: Q2 2011 Highlights
25 Q2 2011 Highlights Revenues of $321.3 million Exceeded rollout goals for Next Generation Posturepedic line Exceeded our goal of having product shipped to 60% of our retailer portfolio by Memorial Day, with 80% rolled out Strong initial response to Posturepedic line at retail Strong performance fr
Slide 27: Investment Highlights
26 Investment Highlights Stabilizing Industry Fundamentals with Attractive Long-Term Prospects Leading Global Brand with Significant Scale Innovative Market Leader with Broadest Branded Product Portfolio Strategic Advertising and Digital Media Assets Unprecedented Opportunity to Gain Profitable Mark
Slide 28: Appendix
27 Appendix
Slide 29: Reconciliation of Non-GAAP Measures
28 Reconciliation of Non-GAAP Measures (In Millions) Our presentation of results includes Adjusted EBITDA which is not recognized under GAAP (Generally Accepted Accounting Principles) and does not purport to be alternatives to net income as a measure of operating performance or to cash flows from op
Slide 30: Illustrative Share Count Roll Forward
29 Illustrative Share Count Roll Forward Below find an illustrative example of the diluted share count. There are many other factors that effect share count, listed below. You should not refer to this table as guidance for actual diluted share count. Other factors affecting diluted share count, whic
Slide 31: Sealy. Whatever you do in bed, supports it.
Sealy. Whatever you do in bed, supports it. gee f 4Posturepedic embody July 2011